Overview

Avipep is developing Avibodies™, as a platform to provide a superior therapeutic window in contrast to conventional intact antibodies. Clinical studies have shown that Avibodies rapidly penetrates tumors, persisting for up to a week while rapidly clearing the systemic circulation without renal uptake. The development of new Antibody Drug Conjugates (ADC) utilising conventional intact antibodies has proven challenging due to their narrow therapeutic window. The current approved intact antibody drug conjugates all have major toxicities and are dosed at Maximum Tolerated Dose (MTD). Avibodies superior biodistribution enables highly potent payloads to be delivered far below the maximum tolerated dose thereby potentially allowing wider range of target antigens to be successful as antibody drug conjugates.